Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, discusses how his company pivoted as a result of the current pandemic, including announced efforts to develop a vaccine for COVID-19.

Chief Editor Rob Wright talks about the first time COVID-19 was mentioned in one of our weekly meets — almost as an afterthought.

In 2006, Pamela Contag, Ph.D. cofounded ConcentRx, but the biopharma rebranded in 2016 to become BioEclipse Therapeutics. The CEO talks about what she learned in those 10 years on that difficult business journey

“Corporate culture will soon be the number one reason why an employee stays or leaves a company.” It’s a comment made to start off a roundtable discussion at the 2020 JPM conference, and we have the details of the discussion here.

I recently met a scientist who had experienced the valley of death firsthand. And rather than have her valley experience be her demise, she instead opted to develop a novel solution. This is her story.

Chief editor Rob Wright shares the difficulty associated with living, working and trying to be productive during the COVID-19 pandemic. 

Axel Hoos, M.D., Ph.D., SVP oncology and R&D governance chair, provides an update and the context of GSK’s R&D strategy.

In reference to Mallinckrodt Pharmaceuticals recent legal issues with drug pricing, chief Editor Rob Wright says transparency in drug pricing is coming and will be driven by a number of stakeholders — including the U.S. federal government.

Chris Anzalone, Ph.D., CEO of Arrowhead Pharmaceuticals, discusses taking over a biopharmaceutical company shortly before the Great Recession along with other avenues of adversity faced (e.g., FDA hold on a Phase 2 trial) toward bringing this RNAi company to the brink of success.